Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.

@article{Arnold2010EfficacyAS,
  title={Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.},
  author={Lesley M. Arnold and R Michael Gendreau and Robert W. H. Palmer and Judy F Gendreau and Yong Wang},
  journal={Arthritis and rheumatism},
  year={2010},
  volume={62 9},
  pages={2745-56}
}
OBJECTIVE To assess the efficacy and safety of milnacipran at a dosage of 100 mg/day (50 mg twice daily) for monotherapy treatment of fibromyalgia. METHODS A double-blind, placebo-controlled trial was performed to assess 1,025 patients with fibromyalgia who were randomized to receive milnacipran 100 mg/day (n = 516) or placebo (n = 509). Patients underwent 4-6 weeks of flexible dose escalation followed by 12 weeks of stable-dose treatment. Two composite responder definitions were used as… CONTINUE READING
37 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Similar Papers

Loading similar papers…